DO-HEALTH-C: Vitamin D3 - Omega3 - Home Exercise - HeALTHy Aging and Longevity Cohort

Sponsor
Heike Bischoff-Ferrari (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05062018
Collaborator
(none)
534
1
37.2
14.4

Study Details

Study Description

Brief Summary

The DO-HEALTH trial will be extended into the cohort including the collection on life style factors such as diet, quality of life and physical activity, as well as health-related data on co-morbid conditions as well as a standardized assessment of multiple organ functions, physical, cognitive and mental function using surveys and standardized health assessments.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The DO-HEALTH cohort will be a continuation of the trial without intervention and will elucidate longterm determinants of healthy, active and independent aging in European community-dwelling older adults. The main emphasize of the cohort will be to determine the risk factors, to quantify the incidence and to describe the trajectories of incident frailty, impaired mobility, loss of independence and age related morbidity (e.g. heart arrhythmia, type 2 diabetes, falls, fractures).

    Additionally, the cohort will continue to investigate the primary endpoints of the original trial like the risk and incidence of injurious falls (bone); functional decline (muscle); high blood pressure (cardiovascular); cognitive decline (brain); and the rate of any infection (immunity). Moreover, the cohort will include and extend key secondary and exploratory endpoints of the original trial such as incidence and prevalence of anemia, sarcopenia, cardiovascular diseases, type 2 diabetes and cancer.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    534 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Vitamin D3 - Omega3 - Home Exercise - HeALTHy Aging and Longevity Cohort
    Actual Study Start Date :
    Nov 26, 2019
    Anticipated Primary Completion Date :
    Dec 31, 2022
    Anticipated Study Completion Date :
    Dec 31, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Incidence of functional decline [24 months]

      assessed by short physical performance test battery

    2. Incidence of injurious falls [24 months]

      assessed by fall questionnaire at each visit

    3. Incidence of high blood pressure [24 months]

      Standardized blood pressure assessment in sitting position

    4. Incidence of cognitive decline [24 months]

      assessed by Montreal Cognitive Assessment (MoCA)

    5. Incidence of infections [24 months]

      assessed by infection questionnaire at each visit

    Secondary Outcome Measures

    1. Incidence and prevalence of frailty [24 months]

      based on criteria by L. Fried (shrinking, weakness, poor endurance and energy, slowness, low physical activity level), SHARE-FI

    2. Incidence and prevalence of impaired mobility [24 months]

      assessed by EQ5D-3L, physical activity questionnaire

    3. Incidence and prevalence of functional dependency [24 months]

      assessed by PROMIS-HAQ

    4. Incidence and prevalence of anemia or iron deficiency [24 months]

      assessed by blood markers (ferritin, soluble transferrin receptor, RBC, Hb, erythrocyte indices (MCV, MCH, MCHC), reticulocytes)

    5. Incidence and prevalence of any cardiovascular disease [24 months]

      assessed by medical history

    6. Incidence and prevalence of heart arrhythmia [24 months]

      assessed by ECG

    7. Incidence and prevalence of atrial fibrillation [24 months]

      assessed by ECG

    8. Incidence and prevalence of heart failure, cardiomyopathy, heart valves abnormalities [24 months]

      assessed by medical history, ECG, physical examination

    9. Incidence of stroke [24 months]

      assessed by medical history

    10. Incidence and prevalence of Type 2 diabetes [24 months]

      assessed by medical history

    11. Incidence and prevalence of dementia [24 months]

      assessed by medical history

    12. Incidence and prevalence of osteoarthritis [24 months]

      assessed by medical history

    13. Incidence and prevalence osteoporosis [24 months]

      assessed by medical history

    14. Incidence and prevalence of sarcopenia, osteosarcopenia [24 months]

      assessed by medical history

    15. Incidence and prevalence of any gastrointestinal disease [24 months]

      assessed by medical history

    16. Incidence and prevalence of gastroesophageal reflux disease (GERD) [24 months]

      assessed by medical history

    17. Incidence and prevalence of any micronutrient deficiency (Vitamins, Minerals and fatty acids) [24 months]

      assessed by medical history

    18. Incidence and prevalence of knee buckling [24 months]

      assessed by medical history, Buckling, KOOS, HOOS

    19. Incidence and prevalence of chronic pain [24 months]

      assessed by medical history, McGill, Joint Map, EQ5D-3L

    20. Incidence and prevalence of subjective memory complaints [24 months]

      assessed by medical history, MoCA, MACQ

    21. Incidence and prevalence of hearing impairment [24 months]

      assessed by medical history, hearing test, physical examination

    22. Incidence and prevalence of depression [24 months]

      assessed by medical history, GDS

    23. Incidence and prevalence insomnia [24 months]

      assessed by medical history, Insomnia

    24. Incidence and prevalence of chronic inflammation [24 months]

      assessed by medical history, blood marker (e.g. CRP)

    25. Incidence and prevalence of polypharmacy [24 months]

      assessed by medication

    26. Incidence and prevalence of inappropriate medication prescription [24 months]

      assessed by medication

    27. Incidence and prevalence of age related morbidity by individual drug use (e.g. Proton-Pump-Inhibitors, anticoagulants, benzodiazepines, antibiotics) [24 months]

      assessed by medication

    28. Incidence and prevalence of malnutrition [24 months]

      assessed by medical history, FFQ, GOHAI, Rome

    29. Incidence and prevalence of urinary incontinence [24 months]

      assessed by medical history, IPPS, QUID

    30. Incidence and prevalence of impaired quality of life [24 months]

      assessed by EQ5D-3L

    31. Incidence and prevalence of functional decline [24 months]

      assessed by medical history

    32. Incidence of fractures [24 months]

      assessed by fracture rate

    33. Incidence of all-cause hospitalization [24 months]

      assessed by medical history

    34. Incidence, prevalence and trajectories of frequent health care utilization [24 months]

      assessed by medical history

    35. Incidence of nursing home placement [24 months]

      assessed by medical history

    36. Incidence of cancer (any cancer, gastro-intestinal, breast cancer in women, prostate cancer in men) [24 months]

      assessed by medical history

    37. Incidence of all-cause mortality [24 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Former participation in the DO-HEALTH clinical trial study
    Exclusion Criteria:
    • Inability or unwillingness to give written informed consent

    • Medical condition that would make the results of the tests/assessments unreliable and/or would put too much burden to the participant, and/or leads to safety concerns.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centre on Aging and Mobility, University of Zurich, City Hospital Zurich Zürich Switzerland

    Sponsors and Collaborators

    • Heike Bischoff-Ferrari

    Investigators

    • Principal Investigator: Heike Bischoff-Ferrari, Prof. Dr. med. DrPH, University of Zurich

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Heike Bischoff-Ferrari, Prof. Dr. med. DrPH, University of Zurich
    ClinicalTrials.gov Identifier:
    NCT05062018
    Other Study ID Numbers:
    • 2019-00134
    First Posted:
    Sep 30, 2021
    Last Update Posted:
    Sep 30, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No

    Study Results

    No Results Posted as of Sep 30, 2021